Abstract
Vemurafenib is increasingly being used to treat nonmelanoma tumors that are positive for the BRAF V600E mutation. We report three children who presented with panniculitis induced by vemurafenib while undergoing treatment for central nervous system tumors and review the literature.
Original language | English (US) |
---|---|
Pages (from-to) | 337-341 |
Number of pages | 5 |
Journal | Pediatric dermatology |
Volume | 34 |
Issue number | 3 |
DOIs | |
State | Published - May 1 2017 |
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Dermatology